Maxx Crosby remains a Las Vegas Raider heading into the 2026 season, despite persistent trade rumors linking the star pass rusher to other organizations. While a potential deal with the Baltimore Ravens collapsed due to medical evaluations of Crosby’s knee, league reports suggest the Raiders are still entertaining inquiries for the right price, according to reporting from Vincent Bonsignore of the New York Post.
Why Did the Ravens Nix the Maxx Crosby Trade?
The proposed deal between the Raiders and the Ravens fell apart primarily due to concerns regarding Crosby’s physical health. According to reports, the evaluation conducted by the Cowboys’ team doctor on Crosby’s knee influenced the broader conversation around his medical status, ultimately causing Baltimore to reconsider the trade. Crosby, who will turn 29 shortly, underwent surgery to repair a torn meniscus in his left knee during the offseason. As of early June 2026, he is reportedly nearing a return to practice, which could provide the medical clearance necessary to change the perception of his long-term prognosis.
Maxx Crosby has secured five consecutive Pro Bowl selections since 2021. Over that same five-year window, he has recorded 52.5 sacks and led the NFL in tackles for loss twice.
What Is the Raiders’ Asking Price for a Trade?
Despite the failed Baltimore deal, the Raiders have not lowered their valuation of the defensive end. According to Vincent Bonsignore, if a team like the San Francisco 49ers were to pursue a trade, the cost would be significant. Reports indicate the Raiders are seeking a package similar to the one the Cleveland Browns received for Myles Garrett. Specifically, this would include a 2027 first-round pick, a 2028 second-round pick, and defensive end Mykel Williams. This high asking price confirms that Las Vegas remains firm on its valuation of one of the league’s most effective run defenders and pass rushers.
How Will Trade Trends Evolve in 2026?
While interest in Crosby remains high, the timing of any potential move is a subject of ongoing speculation. An earlier report from late March suggested that any trade involving Crosby would be more likely to occur closer to the NFL trade deadline. This timeline allows teams to observe Crosby in regular-season competition, providing concrete proof of his knee’s health. Furthermore, by the mid-season point, the Raiders will have a clearer understanding of their own trajectory and whether they remain in contention for a playoff spot, which will dictate their willingness to move a franchise cornerstone.
Pro Tip: Monitoring Trade Deadlines
Keep an eye on how teams manage their roster capital as the season progresses. Organizations that miss out on early-season acquisitions often become more aggressive at the trade deadline, especially when a player’s injury concerns are settled by on-field performance.
Frequently Asked Questions
- Is Maxx Crosby currently on the Raiders’ roster?
Yes, as of June 2026, Crosby remains with the Las Vegas Raiders. - Why was the trade to the Ravens cancelled?
The deal was nixed due to concerns regarding Crosby’s medical history, specifically regarding a torn meniscus in his left knee. - What would a team have to give up to acquire Crosby?
According to reports, the Raiders are seeking a substantial return, including a 2027 first-round pick, a 2028 second-round pick, and defensive end Mykel Williams. - When is the most likely time for a trade?
Reporting suggests that any potential swap is more likely to occur closer to the trade deadline, once a team can evaluate Crosby’s health during the regular season.
What do you think? Should a contending team risk a high-value package for a player with recent knee surgery? Share your thoughts in the comments below or subscribe to our newsletter for the latest NFL trade updates.
Keep reading
- Abankwah Scores Decisive Goal at San Siro
- Sydney Sweeney Slammed by Olympians Over Betting Ad
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)